2016;134:e282 93. 11. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special con- tribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129 200. 12. Packer M, McMurray JJ, Desai AS, et al. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation. 2015;131:54 61. 13. Zile MR, Claggett BL, Prescott MF, et al. Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure. J Am Coll Cardiol. 2016;68:2425 36. 14. Solomon SD, Zile M, Pieske B, et al. The angiotensin receptor nepri- lysin inhibitor LCZ696 in heart failure with preserved ejection frac- tion: a phase 2 double-blind randomised controlled trial. Lancet. 2012;380:1387 95. 15. Richards AM, Doughty R, Nicholls MG, et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and predic- tion of benefit from carvedilol in chronic ischemic left ventricular dys- function. Australia-New Zealand Heart Failure Group. J Am Coll Cardiol. 2001;37:1781 7. 16. Tang WH, Girod JP, Lee MJ, et al. Plasma B-type natriuretic peptide lev- els in ambulatory patients with established chronic symptomatic systolic heart failure. Circulation. 2003;108:2964 6. 17. Zaphiriou A, Robb S, Murray-Thomas T, et al. The diagnostic accuracy of plasma BNP and NTproBNP in patients referred from primary care with suspected heart failure: results of the UK natriuretic peptide study. Eur J Heart Fail. 2005;7:537 41. 18. Son CS, Kim YN, Kim HS, et al. Decision-making model for early diagnosis of congestive heart failure using rough set and decision tree approaches. J Biomed Inform. 